Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 8/20 | 0.48 |
| ▸ | REN known ✓ | P00797 | 1/20 | 0.43 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 10/20 | 0.48 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.48 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30881304 | 1.00 | GPR88 (0.48) | GPR88MMEACESRRPSAT1 | |
| Hydrochloric Acid SCHEMBL598889 | 1.00 | GPR88 (0.48) | GPR88MMEACESRRPSAT1 | |
| Hydrochloric Acid SCHEMBL4440169 | 1.00 | GPR88 (0.48) | GPR88MMEACESRRPSAT1 | |
| SCHEMBL609953 | 0.99 | GPR88 (0.49) | GPR88MMEACESRRPSAT1 | |
| SCHEMBL21572784 | 0.99 | GPR88 (0.49) | GPR88MMEACESRRPSAT1 | |
| SCHEMBL24404055 | 0.99 | GPR88 (0.49) | GPR88MMEACESRRPSAT1 | |
| SCHEMBL18059571 | 0.99 | GPR88 (0.49) | GPR88MMEACESRRPSAT1 | |
| SCHEMBL598890 | 0.99 | GPR88 (0.49) | GPR88MMEACESRRPSAT1 | |
| SCHEMBL597164 | 0.99 | GPR88 (0.49) | GPR88MMEACESRRPSAT1 | |
| SCHEMBL18574633 | 0.99 | GPR88 (0.49) | GPR88MMEACESRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751135-A | Preparation method of Sakuba/valsartan sodium | 苏州东瑞制药有限公司 | 2023-09-15 | — | — | CN | claimed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
| EP-2435462-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | Pfizer Limited (GB) | 2012-04-04 | — | — | EP | claimed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | claimed |
| CN-117447341-B | Refining method of valsartan sodium intermediate of sarcandra | 杭州国瑞生物科技有限公司 | 2025-11-18 | — | — | CN | disclosed |
| CN-119371367-A | Preparation method of sakubi-qu intermediate | 山西库邦生物医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118812371-A | Synthesis method of (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid | 杭州科巢生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115677521-B | Preparation method of high-purity Sha Kuba koji calcium | 迪嘉药业集团股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117447341-A | Refining method of valsartan sodium intermediate of sarcandra | 杭州国瑞生物科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3341364-B1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | HETERO LABS LTD (IN) | 2023-12-20 | — | — | EP | disclosed |
| US-11786498-B2 | Sacubitril calcium salts | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| CN-116751135-A | Preparation method of Sakuba/valsartan sodium | 苏州东瑞制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2435402-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| EP-2435462-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | Pfizer Limited (GB) | 2012-04-04 | — | — | EP | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | ACE 14/4885REN 2/4885MMP8 1997/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | ACE 14/4885REN 2/4885MMP8 1997/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | ACE 43/4885REN 22/4885MMP8 2553/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | ACE 92/4885REN 1/4885MMP8 145/4885 |
| US-11786498-B2 | Sacubitril calcium salts | DNPEP, BPGM, CACNA1S | ACE 31/4885REN 256/4885MMP8 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.